Skip to main content

Table 3 HIV-1 integration events in control and Raltegravir-treated SupT1 cells (a)

From: Antiviral activity of recombinant ankyrin targeted to the capsid domain of HIV-1 Gag polyprotein

Sequence
amplified
Raltegravir (nM)
  0 1 10 100
Alu-gag junctions 26.9 ± 0.2 36.1 ± 0.3 ND ND
GAPDH 23.3 ± 0.5 23.7 ± 0.4 24.1 ± 0.3 23.9 ± 0.2
  1. (a) Aliquots of HIV-1-infected SupT1 cells were pretreated with Raltegravir at 0, 1, 10, and 100 nM, respectively, for 24 hr prior to HIV-1 infection (MOI 10), and the drug maintained at the indicated concentrations for 7 days. Host cell genomic DNA was extracted on day 7 pi, and the level of HIV-1 integration in SupT1 cell lines was evaluated by quantitative PCR amplification of DNA extracts, using primers specific to Alu-gag junctions and to cellular GAPDH gene as the internal control. Figures shown in the Table are Cts values (mean ± SD, n = 3). ND, not detectable (below the threshold of detection).